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Abstract
The canonical Notch signalling pathway has four type I transmembrane Notch receptors (Notch1-4) and five
ligands (DLL1, 2 and 3, and Jagged 1-2). Each member of this highly conserved receptor family plays a unique
role in cell-fate determination during embryogenesis, differentiation, tissue patterning, proliferation and cell death
[2]. As the Notch ligands are also membrane bound, cells have to be in close proximity for receptor-ligand
interactions to occur. Cleavage of the intracellular domain (ICD) of activated Notch receptors by γ-secretase is
required for downstream signalling and Notch-induced transcriptional modulation [15, 3, 11, 22]. This is why γ-
secretase inhibitors can be used to downregulate Notch signalling and explains their anti-cancer action. One
such small molecule is RO4929097 [8], although development of this compound has been terminated following
an unsuccessful Phase II single agent clinical trial in metastatic colorectal cancer [19].
Aberrant Notch signalling is implicated in a number of human cancers [12, 20, 6, 16], with demcizumab and
tarextumab identified as antibody inhibitors of ligand:receptor binding [13].
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